首页> 美国卫生研究院文献>Aging (Albany NY) >Overexpression of LINC00160 predicts poor outcome and promotes progression of clear cell renal cell carcinoma
【2h】

Overexpression of LINC00160 predicts poor outcome and promotes progression of clear cell renal cell carcinoma

机译:LINC00160的过表达预示不良结果并促进透明细胞肾细胞癌的进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal carcinoma and exhibits a high risk of invasion and metastasis. It is urgent to uncover a novel biomarker and clarify the underlying mechanism for ccRCC progression and metastasis. Although accumulating research has demonstrated that long non-coding RNAs (lncRNAs) play crucial roles in tumor progression, numerous lncRNAs in ccRCC are largely unknown. Therefore, we screened the differentially expressed lncRNAs among several GEO datasets and chose LNC00160 for further investigation. LNC00160 was significantly upregulated in ccRCC and high expression predicted poor prognosis; higher expression of LNC00160 was associated with advanced clinic pathological parameters in TCGA_KIRC Cohort. Knockdown of LNC00160 suppressed malignancy of ccRCC in and in . Correlation analysis and gene set enrichment analysis (GSEA) revealed that LNC00160 might be associated with Wnt signaling pathway, mTOR signaling pathway, fatty acid metabolism and cell cycle. In conclusion, our results demonstrated that LNC00160 acted as an oncogenic gene and a specific prognostic indicator for patients with ccRCC, and that LNC00160 might be a targeted intervention for ccRCC patients in the future.
机译:透明细胞肾细胞癌(ccRCC)是最常见的肾癌亚型,具有高侵袭和转移风险。迫切需要发现一种新的生物标记并阐明ccRCC进展和转移的潜在机制。尽管越来越多的研究表明,长的非编码RNA(lncRNA)在肿瘤进展中起着至关重要的作用,但ccRCC中的许多lncRNA仍是未知的。因此,我们筛选了几个GEO数据集之间差异表达的lncRNA,并选择了LNC00160进行进一步研究。 LNC00160在ccRCC中显着上调,高表达预后不良。 LNC00160的较高表达与TCGA_KIRC队列中晚期临床病理参数有关。敲除LNC00160可抑制ccRCC的恶性病变。相关分析和基因集富集分析(GSEA)表明,LNC00160可能与Wnt信号通路,mTOR信号通路,脂肪酸代谢和细胞周期有关。总之,我们的结果表明LNC00160是ccRCC患者的致癌基因和特定的预后指标,并且LNC00160将来可能是ccRCC患者的靶向干预措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号